Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KURA Kura Oncology

Pre-Mkt 06-22 09:28:03 EDT

9.93

+0.36

+3.76%

盘前10.07

+0.14+1.41%

09:27 EDT

High9.98	Low9.55	Vol1.70M
Open9.67	D1 Closing9.57	Amplitude4.49%
Mkt Cap881.53M	Tradable Cap635.38M	Total Shares88.77M
T/O16.68M	T/O Rate2.66%	Tradable Shares63.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KURA","market":"US","secType":"STK","nameCN":"Kura Oncology","latestPrice":9.93,"timestamp":1781812800000,"preClose":9.57,"halted":0,"volume":1700089,"hourTrading":{"tag":"盘前","latestPrice":10.07,"preClose":9.93,"latestTime":"09:27 EDT","volume":1993,"amount":20030.473109000002,"timestamp":1782134855306,"change":0.14,"changeRate":0.014099,"amplitude":0.026183},"delay":0,"changeRate":0.03761755485893411,"floatShares":63985582,"shares":88774365,"eps":-3.348347,"marketStatus":"Pre-Mkt","change":0.36,"latestTime":"06-22 09:28:03 EDT","open":9.67,"high":9.98,"low":9.55,"amount":16676968.642652001,"amplitude":0.044932,"askPrice":10.1,"askSize":5,"bidPrice":9.9,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-3.348347,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782135000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1446699600000,"exchange":"NASDAQ","adjPreClose":9.93,"preHourTrading":{"tag":"盘前","latestPrice":10.07,"preClose":9.93,"latestTime":"09:27 EDT","volume":1993,"amount":20030.473109000002,"timestamp":1782134855306,"change":0.14,"changeRate":0.014099,"amplitude":0.026183},"postHourTrading":{"tag":"盘后","latestPrice":9.93,"preClose":9.93,"latestTime":"17:45 EDT","volume":160578,"amount":1589888.1117,"timestamp":1781819141451,"change":0,"changeRate":0,"amplitude":0.024169},"volumeRatio":1.0592119421724855,"impliedVol":0.4449,"impliedVolPercentile":0.2},"requestUrl":"/m/hq/s/KURA/tweets","defaultTab":"tweets","newsList":[{"id":"2643201310","title":"Kura Oncology Price Target Maintained With a $24.00/Share by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201310","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643201310?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:09","pubTimestamp":1781532540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 10:09 ET (14:09 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643859206","title":"Wedbush Remains a Buy on Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643859206","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643859206?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:55","pubTimestamp":1781528142,"startTime":"0","endTime":"0","summary":"Wedbush analyst reiterated a Buy rating on Kura Oncology today and set a price target of $36.00. Kura Oncology has an analyst consensus of Strong B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643294455","title":"Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643294455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643294455?lang=en_us&edition=fundamental","pubTime":"2026-06-13 00:30","pubTimestamp":1781281817,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MBX Biosciences, Inc. (MBX) and Kura Oncology (KURA)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-mbx-biosciences-inc-mbx-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-mbx-biosciences-inc-mbx-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4588","BK4581","HCSG","BK4007","LABU","BK4139","BK4585","KURA","BK4137","MBX","XBI","XLV","LU0128526141.USD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642295613","title":"Kura Oncology posts EHA investor deck detailing ziftomenib AML clinical update","url":"https://stock-news.laohu8.com/highlight/detail?id=2642295613","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642295613?lang=en_us&edition=fundamental","pubTime":"2026-06-12 21:27","pubTimestamp":1781270845,"startTime":"0","endTime":"0","summary":"Kura Oncology highlighted KOMZIFTI  FDA clearance for adult relapsed or refractory NPM1-mutated AML.Reported early launch momentum, with plans to expand ziftomenib use toward up to 50% of AML patients.Venetoclax-experienced patients showed ORR 48%; median overall survival 7.4 months; median CRc duration of response 8.6 months.Cash and investments totaled USD 580.8 million as of 3/31/26; additional USD 180 million in anticipated payments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL3jwBsF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282219","title":"BUZZ-Kura Oncology up as leukemia drug shows strong survival in early- to mid-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282219","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282219?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:04","pubTimestamp":1781183045,"startTime":"0","endTime":"0","summary":"BUZZ-Kura Oncology up as leukemia drug shows strong survival in early- to mid-stage trial** Shares of biotech firm Kura Oncology KURA.O rise around 3% to $8.99 in premarket trading** Experimental drug ziftomenib helped treat acute myeloid leukemia, a fast-growing blood cancer affecting the bone marrow, in an early- to mid-stage trial, co says** Most patients had no measurable disease and responses lasted over time, co says** Adds, safety profile was manageable with no new concerns, with data supporting late-stage study KOMET-017 in newly diagnosed patients** As of last close, stock down around 16% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nL4N42J0YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282683","title":"Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282683","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282683?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:55","pubTimestamp":1781182501,"startTime":"0","endTime":"0","summary":"Kura Oncology  and Kyowa Kirin reported long-term data showing high remission rates and favorable survival outcomes for ziftomenib in combination with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia, the companies said Thursday.Among NPM1-mutated patients, the combination achieved a 96% composite complete remission rate and a 94% estimated overall survival rate at 12 months.. Patients with KMT2A-rearranged AML achieved a 90% composite complete remission rate and a 71% 12 month overall survival rate, according to the companies.The treatment maintained a consistent and manageable safety profile, with no new safety signals identified during extended follow-up, the companies said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281404","title":"Kura Oncology reports 94% 12-month survival in KOMET-007 trial of ziftomenib plus 7+3 in newly diagnosed NPM1-mutant AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281404","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281404?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:06","pubTimestamp":1781179589,"startTime":"0","endTime":"0","summary":"Kura Oncology reported long-term results from the Phase 1/2 KOMET-007 trial of ziftomenib with standard intensive chemotherapy in newly diagnosed AML.Results will be presented at the European Hematology Association 2026 Congress.The single-arm study showed high remission rates, deep molecular responses, durable benefit, favorable survival trends, and manageable safety across key genetic subtypes.Data supported confidence in the ongoing Phase 3 KOMET-017 registrational program testing the same approach in frontline AML.Ziftomenib remains FDA-cleared only as monotherapy in relapsed or refractory NPM1-mutant AML; the frontline combination remains investigational.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL6QbHSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642814412","title":"Kura Oncology - Ziftomenib 600 Mg Once-Daily Plus 7+3 Well Tolerated With No New Safety Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2642814412","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642814412?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:04","pubTimestamp":1781179452,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0XO:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281489","title":"Kura Oncology and Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination in Newly Diagnosed Aml","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281489?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:04","pubTimestamp":1781179452,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281435","title":"Kura Oncology - Reports 12-Month Os Rate of 94% in Npm1-M Aml, 71% in Kmt2a-R Aml","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281435?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:04","pubTimestamp":1781179452,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0XO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KURA","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282894","title":"Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282894","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282894?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:02","pubTimestamp":1781179320,"startTime":"0","endTime":"0","summary":"– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – – ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310431/35186/en/Kura-Oncology-And-Kyowa-Kirin-Report-Encouraging-Long-Term-Results-for-Ziftomenib-7-3-Combination-In-Newly-Diagnosed-AML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641607481","title":"Analysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH), Kura Oncology (KURA) and Hyperion DeFi (HYPD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641607481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641607481?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:00","pubTimestamp":1780920024,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aveanna Healthcare Holdings (AVAH), Kura Oncology (KURA) and Hype...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-aveanna-healthcare-holdings-avah-kura-oncology-kura-and-hyperion-defi-hypd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-aveanna-healthcare-holdings-avah-kura-oncology-kura-and-hyperion-defi-hypd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","HYPD","AVAH","BK4539","BK4585","XLV","KURA","XBI","BK4007","LABU","BK4581","BK4196","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641414241","title":"Kura Oncology Advances Targeted Combo in Tough Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2641414241","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641414241?lang=en_us&edition=fundamental","pubTime":"2026-06-06 00:32","pubTimestamp":1780677120,"startTime":"0","endTime":"0","summary":"Kura Oncology ($KURA) announced an update on their ongoing clinical study. The phase 1/2 trial NCT04997902 tests a drug combo from Kura Oncology fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kura-oncology-advances-targeted-combo-in-tough-head-and-neck-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kura-oncology-advances-targeted-combo-in-tough-head-and-neck-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641711712","title":"Kura Oncology grants 53,000 inducement stock options at $9.04 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2641711712","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641711712?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:30","pubTimestamp":1780659018,"startTime":"0","endTime":"0","summary":"Kura Oncology set inducement stock option awards for four new employees covering 53,000 shares under its amended 2023 Inducement Option Plan.Options carry a $9.04 exercise price, set at the June 1 closing share price.Vesting runs four years: 25% after one year, then monthly over the next 36 months, subject to continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL7chPgt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","NDAQ","SG9999014021.USD","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","LU0314104364.USD","IE00BN0W2W23.USD","KURA","IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","SG9999014039.USD","BK4505","LU2095319765.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117190","title":"Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641117190?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:30","pubTimestamp":1780659000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nTUABQCGHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641170741","title":"Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641170741","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641170741?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:30","pubTimestamp":1780659000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, June  05, 2026  (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307309/35186/en/Kura-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","KURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641196520","title":"Lake Street Initiates a Buy Rating on Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641196520","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641196520?lang=en_us&edition=fundamental","pubTime":"2026-06-05 09:17","pubTimestamp":1780622227,"startTime":"0","endTime":"0","summary":"Lake Street analyst Daniel Brims initiated coverage with a Buy rating on Kura Oncology yesterday and set a price target of $23.00. According to Tip...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-initiates-a-buy-rating-on-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-initiates-a-buy-rating-on-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641608791","title":"Kura Oncology Shareholders Approve Expanded Equity Incentive Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2641608791","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641608791?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:13","pubTimestamp":1780607638,"startTime":"0","endTime":"0","summary":"Kura Oncology ( ($KURA) ) just unveiled an announcement. On April 9, 2026, Kura Oncology’s board approved amendments to its 2014 Equity Incentive P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kura-oncology-shareholders-approve-expanded-equity-incentive-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kura-oncology-shareholders-approve-expanded-equity-incentive-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","BK4588","KURA","BK4215","BK4585","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641216230","title":"Kura Oncology expands 2014 equity incentive plan share reserve to 41,077,686 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2641216230","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641216230?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:08","pubTimestamp":1780603697,"startTime":"0","endTime":"0","summary":"Kura Oncology updated its amended and restated 2014 equity incentive plan, keeping employees, directors, and consultants eligible for awards.The plan’s share reserve was set at 41,077,686 shares, including 6,500,000 shares added with stockholder approval at the 2026 annual meeting.Non-employee director pay was capped at USD 750,000 per annual period, rising to USD 1,000,000 for first-time directors.The plan limits option and SAR repricing, barring underwater cancellations for cash or new awards without stockholder approval within 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval sy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL4c9SqS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640616825","title":"Wedbush Sticks to Its Buy Rating for Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640616825","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640616825?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:35","pubTimestamp":1780580134,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush reiterated a Buy rating on Kura Oncology, with a price target of $36.00. In a report released today, Barcl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KURA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kuraoncology.com","stockEarnings":[{"period":"1week","weight":0.1208},{"period":"1month","weight":0.1083},{"period":"3month","weight":0.2022},{"period":"6month","weight":0.0091},{"period":"1year","weight":0.6386},{"period":"ytd","weight":-0.0443}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.002309},{"month":2,"riseRate":0.545455,"avgChangeRate":0.031825},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.033425},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.021049},{"month":5,"riseRate":0.545455,"avgChangeRate":0.027851},{"month":6,"riseRate":0.454545,"avgChangeRate":0.031781},{"month":7,"riseRate":0.5,"avgChangeRate":0.037366},{"month":8,"riseRate":0.5,"avgChangeRate":0.066679},{"month":9,"riseRate":0.5,"avgChangeRate":0.12103},{"month":10,"riseRate":0.3,"avgChangeRate":-0.077132},{"month":11,"riseRate":0.8,"avgChangeRate":0.052179},{"month":12,"riseRate":0.454545,"avgChangeRate":0.00367}],"exchange":"NASDAQ","name":"Kura Oncology","nameEN":"Kura Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kura Oncology(KURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kura Oncology,KURA,Kura Oncology股票,Kura Oncology股票老虎,Kura Oncology股票老虎国际,Kura Oncology行情,Kura Oncology股票行情,Kura Oncology股价,Kura Oncology股市,Kura Oncology股票价格,Kura Oncology股票交易,Kura Oncology股票购买,Kura Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kura Oncology(KURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kura Oncology(KURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}